Cellebrite stock falls 3.08 percent, 44.79 percent below its 52-week high

Published on 10/17/2026 at 21:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Results are estimated for November 11, 2026. Cellebrite stock stood at USD 11.03 on October 16, 2026, down 3.08 percent versus Nasdaq's prior close.

Trading and earnings dates

Cellebrite finished its October 16, 2026 Nasdaq session lower.
MarketBeat estimates the next report for November 11, 2026.
Cellebrite stock stood at USD 11.03 on October 16, 2026 at 4:00 p.m. ET, down 3.08 percent versus the Nasdaq prior close.
Cellebrite's P/E was 47.16 at a USD 2.8 billion market capitalization.

CLBT, IL0011794802, Illustration mit AI erstellt.

Cellebrite stock fell 3.08 percent on Nasdaq on October 16, 2026, leaving it 44.79 percent below its 52-week high. MarketBeat estimates the next quarterly report for November 11, 2026. Cellebrite stock stood at USD 11.03 on October 16, 2026 at 4:00 p.m. ET, down 3.08 percent versus the Nasdaq prior close of October 15, 2026.

Third-quarter outlook spans USD 145 million

The company enters that reporting date with management guidance for third-quarter revenue of USD 145 million to USD 148 million and adjusted EBITDA of USD 42 million to USD 45 million. The ranges were presented during the second-quarter 2026 earnings call on August 13, 2026, when management also projected adjusted EBITDA margins of 29 percent to 30 percent. Yahoo Finance carries the transcript and the outlook.

Price position and trading activity

The October 16 close of USD 11.03 sits between the 52-week low of USD 9.58 and high of USD 19.98. That leaves the stock 15.14 percent above its low and 44.79 percent below its high. Trading volume was 1,532,211 shares, compared with an average volume of 3,003,635 shares, while the market capitalization stood at USD 2.8 billion.

Valuation and the next date

Cellebrite carried a trailing P/E ratio of 47.16 as of October 16, 2026. MarketBeat lists USD 0.17 in expected earnings per share and USD 145.89 million in expected revenue for the third quarter, alongside the November 11, 2026 reporting date. The date is the next scheduled checkpoint for the outlook ranges above.

Comparison with peers

Cellebrite (Nasdaq, USD): minus 3.08 percent, P/E 47.16, market capitalization USD 2.8 billion
Axon Enterprise (Nasdaq, USD): minus 6.45 percent, P/E 161.81, market capitalization USD 31.7 billion
Veritone (Nasdaq, USD): minus 2.70 percent, P/E minus 0.43, market capitalization USD 54.9 million

Nasdaq close leaves a wide range

The Nasdaq closing price was USD 11.03 on October 16, 2026 at 4:00 p.m. ET, down 3.08 percent versus the prior close of October 15, 2026. The stock's valuation and its distance from the 52-week high put the November reporting date at the center of the next market assessment.